by Alex Kadhim
Researchers from Massachusetts General Hospital, the Krantz Family Center for Cancer Research, and Harvard Medical School have demonstrated that a tandem CAR-T cell targeting mesothelin and MUC16...
by Alex Kadhim
n a collaborative effort, researchers from the University of Oxford, Imperial College London, and Great Ormond Street Hospital have found that bi-specific CD19–CD133 CAR-invariant NKT cells...
by Alex Kadhim
Researchers at University College London and collaborators have determined that matched allogeneic donor CD19 CAR T-cell therapy, delivered as a CAR-modified donor lymphocyte infusion, is safe and...
by Alex Kadhim
Researchers at University Hospital Erlangen and collaborators have observed that CD19 CAR T-cell therapy has a more favorable safety profile in systemic lupus erythematosus (SLE) than in B-cell...
by Alex Kadhim
Researchers from MD Anderson investigated why some follicular lymphoma (FL) patients experience benefit from axicabtagene ciloleucel (axi-cel) while others relapse or develop severe toxicities....
by Alex Kadhim
Researchers from King’s College London and collaborators have investigated how different CAR-T products imprint distinct metabolic programs following infusion in patients with...